Vidyya Medical News Service
*
Volume 5 Issue 282 Published - 14:00 UTC 08:00 EST 9-Oct-2003 Next Update - 14:00 UTC 08:00 EST 10-Oct-2003
little clear gif used for spacer
.
*

FDA approves Inspra for improving survival of congestive heart failure patients after a heart attack
The Food and Drug Administration (FDA) yesterday announced the approval of Inspra (eplerenone) tablets for improving the survival of congestive heart failure patients following an acute heart attack.  more

*
Congestive heart failure in the United States: An epidemic
An estimated 4.8 million Americans have congestive heart failure (CHF). Increasing prevalence, hospitalizations, and deaths have made CHF a major chronic condition in the United States. It often is the end stage of cardiac disease. Half of the patients diagnosed with CHF will be dead within 5 years. Each year, there are an estimated 400,000 new cases.  more

 


*
Prescribing information: Inspra (eplerenone)
Inspra is the first member of the aldosterone receptor blocker class of drugs to receive approval for this indication. The use of Inspra in the placebo-controlled clinical trial supporting its approval resulted in a significant (15%) reduction in the risk of death. The reduction in the risk of death and improved survival with Inspra occurred in patients who were typically receiving other appropriate therapy.  more

*
It's never too late to exercise
Older Americans need more motivation to exercise regularly, say a series of studies published in the American Journal of Preventive Medicine.  more

*
Asthmatic children who use maintenance medication particularly vulnerable to effects of ground-level ozone
New evidence gathered in a study funded by the National Institute of Environmental Health Sciences suggests that asthmatic children who use maintenance medication are particularly vulnerable to the effects of ground-level ozone, even at levels well below the federal standard set by the Environmental Protection Agency.  more

 
little clear gif used for a space